# BIONDVAX PHARMACEUTICALS LTD (BVXV)

> Institutional ownership reported to the SEC as of Q3 2022, from Form 13F filings. Source: https://holderbook.com/stocks/BVXV/

- Reporting holders: 10
- Reported value: $153.0K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [ENVESTNET ASSET MANAGEMENT INC](https://holderbook.com/funds/1407543-envestnet-asset-management-inc/) | $58.0K | 79,216 | 0.0% | 4 |
| [TRUE Private Wealth Advisors](https://holderbook.com/funds/1667074-true-private-wealth-advisors/) | $34.0K | 47,000 | 0.0% | 7 |
| [MORGAN STANLEY](https://holderbook.com/funds/895421-morgan-stanley/) | $17.0K | 22,590 | 0.0% | 20 |
| [RENAISSANCE TECHNOLOGIES LLC](https://holderbook.com/funds/1037389-renaissance-technologies-llc/) | $13.0K | 18,400 | 0.0% | 2 |
| [GEODE CAPITAL MANAGEMENT, LLC](https://holderbook.com/funds/1214717-geode-capital-management-llc/) | $10.0K | 13,768 | 0.0% | 9 |
| [MILLENNIUM MANAGEMENT LLC](https://holderbook.com/funds/1273087-millennium-management-llc/) | $9.0K | 12,275 | 0.0% | 1 |
| [UBS Group AG](https://holderbook.com/funds/1610520-ubs-group-ag/) | $6.0K | 8,048 | 0.0% | 6 |
| [CREDIT AGRICOLE S A](https://holderbook.com/funds/1191672-credit-agricole-s-a/) | $3.0K | 4,240 | 0.0% | 7 |
| [ROYAL BANK OF CANADA](https://holderbook.com/funds/1000275-royal-bank-of-canada/) | $2.0K | 2,540 | 0.0% | 16 |
| [Aspire Private Capital, LLC](https://holderbook.com/funds/1767340-aspire-private-capital-llc/) | $1.0K | 1,600 | 0.0% | 3 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2022 | 10 | $153.0K |
| Q2 2022 | 13 | $389.0K |
| Q1 2022 | 17 | $544.3K |
| Q4 2021 | 13 | $789.0K |
| Q3 2021 | 15 | $560.0K |
| Q2 2021 | 15 | $891.0K |
| Q1 2021 | 17 | $1.1M |
| Q4 2020 | 11 | $623.0K |
| Q3 2020 | 18 | $21.1M |
| Q2 2020 | 14 | $11.5M |
| Q1 2020 | 8 | $3.1M |
| Q4 2019 | 11 | $4.4M |